Analyst Ratings for Esperion Therapeutics (ESPR)
ESPR Rating Summary
ESPR Price Target Summary
- Highest: $90.00 (Cantor Fitzgerald)
- Lowest: $4.00 (Citizens)
- Average: $29.75
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$29.75 (+989.7%)
* Over Last 12-Mos
Rating Score: 5.2 / 10
Percentile Rank: 56%
Avg. $ Target:
$29.75 (+989.7%)
* Over Last 12-Mos
Rating Score: 5.2 / 10
Percentile Rank: 56%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/25/2025 | Piper Sandler | David Amsellem | New Coverage | Overweight (N/A) |
9.00 (N/A) |
3.08 (2.73) |
-11.36% | Details |
| 12/18/2024 | Goldman Sachs » Updated 4/16/2025 |
Paul Choi | New Coverage | Neutral (N/A) |
3.00 (4.00) |
2.33 (2.73) |
17.17% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
